|
1
|
Jia Y, Li F, Liu YF, Zhao JP, Leng MM and
Chen L: Depression and cancer risk: A systematic review and
meta-analysis. Public Health. 149:138–148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Devarakonda S, Morgensztern D and Govindan
R: Genomic alterations in lung adenocarcinoma. Lancet Oncol.
16:e342–e351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pao W and Miller VA: Epidermal growth
factor receptor mutations, small-molecule kinase inhibitors, and
non-small-cell lung cancer: Current knowledge and future
directions. J Clin Oncol. 23:2556–2568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cho J, Choi SM, Lee J, Lee CH, Lee SM, Yim
JJ, Chung DH, Yoo CG, Kim YW, Han SK and Park YS: The association
of EGFR mutations with stage at diagnosis in lung adenocarcinomas.
PLoS One. 11:e01668212016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP
and He ZY: The association between clinical prognostic factors and
epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) efficacy in advanced non-small-cell lung cancer
patients: A retrospective assessment of 94 cases with EGFR
mutations. Oncotarget. 8:3412–3421. 2017.PubMed/NCBI
|
|
8
|
Na II, Rho JK, Choi YJ, Kim CH, Park JH,
Koh JS, Ryoo BY, Yang SH and Lee JC: The survival outcomes of
patients with resected non-small cell lung cancer differ according
to EGFR mutations and the P21 expression. Lung Cancer. 57:96–102.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eichler AF, Kahle KT, Wang DL, Joshi VA,
Willers H, Engelman JA, Lynch TJ and Sequist LV: EGFR mutation
status and survival after diagnosis of brain metastasis in nonsmall
cell lung cancer. Neuro Oncol. 12:1193–1199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Isaka T, Nakayama H, Yokose T, Ito H,
Miyagi Y, Matsuzaki T, Nagata M, Furumoto H, Nishii T, Katayama K,
et al: Epidermal growth factor receptor mutations and prognosis in
pathologic N1-N2 pulmonary adenocarcinoma. Ann Thorac Surg.
102:1821–1828. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dancey JE: Epidermal growth factor
receptor inhibitors in non-small cell lung cancer. Drugs.
67:1125–1138. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matsumura Y, Owada Y, Yamaura T, Muto S,
Osugi J, Hoshino M, Higuchi M, Ohira T, Suzuki H and Gotoh M:
Epidermal growth factor receptor gene mutation as risk factor for
recurrence in patients with surgically resected lung
adenocarcinoma: A matched-pair analysis. Interact Cardiovasc Thorac
Surg. 23:216–222. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshizawa A, Sumiyoshi S, Sonobe M,
Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H
and Haga H: Validation of the IASLC/ATS/ERS lung adenocarcinoma
classification for prognosis and association with EGFR and KRAS
gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol.
8:52–61. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Memon AA, Zhang H, Gu Y, Luo Q, Shi J,
Deng Z, Ma J and Ma W: EGFR with TKI-sensitive mutations in exon 19
is highly expressed and frequently detected in Chinese patients
with lung squamous carcinoma. Onco Targets Ther. 10:4607–4613.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Russell PA, Barnett SA, Walkiewicz M,
Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D
and John T: Correlation of mutation status and survival with
predominant histologic subtype according to the new IASLC/ATS/ERS
lung adenocarcinoma classification in stage III (N2) patients. J
Thorac Oncol. 8:461–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun Y, Hou L, Yang Y, Xie H, Yang Y, Li Z,
Zhao H, Gao W and Su B: Two-gene signature improves the
discriminatory power of IASLC/ATS/ERS classification to predict the
survival of patients with early-stage lung adenocarcinoma. Onco
Targets Ther. 9:4583–4591. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim D, Kim HK, Kim SH, Lee HY, Cho JH,
Choi YS, Kim K, Kim J, Zo JI and Shim YM: Prognostic significance
of histologic classification and tumor disappearance rate by
computed tomography in lung cancer. J Thorac Dis. 10:388–397. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Abdollah F, Sun M, Suardi N, Gallina A,
Capitanio U, Bianchi M, Tutolo M, Passoni N, Karakiewicz PI,
Rigatti P, et al: National Comprehensive Cancer Network practice
guidelines 2011: Need for more accurate recommendations for pelvic
lymph node dissection in prostate cancer. J Urol. 188:423–428.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G,
Garg K, et al: International association for the study of lung
cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Warth A, Muley T, Meister M, Stenzinger A,
Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H and
Weichert W: The novel histologic International Association for the
Study of Lung Cancer/American Thoracic Society/European Respiratory
Society classification system of lung adenocarcinoma is a
stage-independent predictor of survival. J Clin Oncol.
30:1438–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Angulo B, Conde E, Suárez-Gauthier A,
Plaza C, Martínez R, Redondo P, Izquierdo E, Rubio-Viqueira B,
Paz-Ares L, Hidalgo M, et al: A comparison of EGFR mutation testing
methods in lung carcinoma: Direct sequencing, real-time PCR and
immunohistochemistry. PLoS One. 7:e438422012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Cai Y, Dong Y, Nong J, Zhou L, Liu
G, Su D, Li X, Wu S, Chen X, et al: Clinical characteristics and
outcomes of patients with primary lung adenocarcinoma harboring ALK
rearrangements detected by FISH, IHC, and RT-PCR. PLoS One.
9:e1015512014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim EK, Kim KA, Lee CY and Shim HS: The
frequency and clinical impact of HER2 alterations in lung
adenocarcinoma. PLoS One. 12:e01712802017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi Y, Au JS, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Midha A, Dearden S and McCormack R: EGFR
mutation incidence in non-small-cell lung cancer of adenocarcinoma
histology: A systematic review and global map by ethnicity
(mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
|
|
27
|
Martin P, Shiau CJ, Pasic M, Tsao M,
Kamel-Reid S, Lin S, Tudor R, Cheng S, Higgins B, Burkes R, et al:
Clinical impact of mutation fraction in epidermal growth factor
receptor mutation positive NSCLC patients. Br J Cancer.
114:616–622. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wei WE, Mao NQ, Ning SF, Li JL, Liu HZ,
Xie T, Zhong JH, Feng Y, Wei CH and Zhang LT: An analysis of EGFR
mutations among 1506 cases of non-small cell lung cancer patients
in Guangxi, China. PLoS One. 11:e01687952016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Won YW, Han JY, Lee GK, Park SY, Lim KY,
Yoon KA, Yun T, Kim HT and Lee JS: Comparison of clinical outcome
of patients with non-small-cell lung cancer harbouring epidermal
growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol.
64:947–952. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang
T, Han Y, Huang L, Zhu Y, Li X and Yan X: EGFR mutations in
surgically resected fresh specimens from 697 consecutive Chinese
patients with non-small cell lung cancer and their relationships
with clinical features. Int J Mol Sci. 14:24549–24559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Riely GJ, Pao W, Pham D, Li AR, Rizvi N,
Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M and Miller VA:
Clinical course of patients with non-small cell lung cancer and
epidermal growth factor receptor exon 19 and exon 21 mutations
treated with gefitinib or erlotinib. Clin Cancer Res. 12:839–844.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee VH, Tin VP, Choy TS, Lam KO, Choi CW,
Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, et al: Association of
exon 19 and 21 EGFR mutation patterns with treatment outcome after
first-line tyrosine kinase inhibitor in metastatic non-small-cell
lung cancer. J Thorac Oncol. 8:1148–1155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gazdar AF and Minna JD: Inhibition of EGFR
signaling: All mutations are not created equal. PLoS Med.
2:e3772005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carey KD, Garton AJ, Romero MS, Kahler J,
Thomson S, Ross S, Park F, Haley JD, Gibson N and Sliwkowski MX:
Kinetic analysis of epidermal growth factor receptor somatic mutant
proteins shows increased sensitivity to the epidermal growth factor
receptor tyrosine kinase inhibitor, erlotinib. Cancer Res.
66:8163–8171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Beau-Faller M, Prim N, Ruppert AM,
Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet
JL, Rouquette I, et al: Rare EGFR exon 18 and exon 20 mutations in
non-small-cell lung cancer on 10 117 patients: A multicentre
observational study by the French ERMETIC-IFCT network. Ann Oncol.
25:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Watanabe S, Minegishi Y, Yoshizawa H,
Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma
A, et al: Effectiveness of gefitinib against non-small-cell lung
cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac
Oncol. 9:189–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang Q, Ke E, Niu F, Deng W, Chen Z, Xu
C, Zhang X, Zhao N, Su J, Yang J, et al: The role of T790M mutation
in EGFR-TKI re-challenge for patients with EGFR-mutant advanced
lung adenocarcinoma. Oncotarget. 8:4994–5002. 2017.PubMed/NCBI
|
|
38
|
Su KY, Chen HY, Li KC, Kuo ML, Yang JC,
Chan WK, Ho BC, Chang GC, Shih JY, Yu SL and Yang PC: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sumiyoshi S, Yoshizawa A, Sonobe M,
Kobayashi M, Fujimoto M, Tsuruyama T, Date H and Haga H: Pulmonary
adenocarcinomas with micropapillary component significantly
correlate with recurrence, but can be well controlled with EGFR
tyrosine kinase inhibitors in the early stages. Lung Cancer-J
Iaslc. 81:53–59. 2013. View Article : Google Scholar
|
|
40
|
Ohtaki Y, Shimizu K, Kakegawa S, Nagashima
T, Nakano T, Atsumi J, Enokida Y, Igai H, Ibe T, Sugano M, et al:
Postrecurrence survival of surgically resected pulmonary
adenocarcinoma patients according to EGFR and KRAS mutation status.
Mol Clin Oncol. 2:187–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li J, Yang X, Xia T, Guan Y and Zhong N:
Stage I synchronous multiple primary non-small cell lung cancer: CT
findings and the effect of TNM staging with the 7th and 8th
editions on prognosis. J Thorac Dis. 9:5335–5344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ramlau R, Krawczyk P, Dziadziuszko R,
Chmielewska I, Milanowski J, Olszewski W, Stencel K, Ramlau-Piątek
K, Segiet A, Skroński M, et al: Predictors of EGFR mutation and
factors associated with clinical tumor stage at diagnosis:
Experience of the INSIGHT study in Poland. Oncol Lett.
14:5611–5618. 2017.PubMed/NCBI
|
|
43
|
Saji H, Tsuboi M, Shimada Y, Kato Y,
Yoshida K, Nomura M, Matsubayashi J, Nagao T, Kakihana M, Usuda J,
et al: A proposal for combination of total number and anatomical
location of involved lymph nodes for nodal classification in
non-small cell lung cancer. Chest. 143:1618–1625. 2013. View Article : Google Scholar : PubMed/NCBI
|
